Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022.

Authors: Alrasheed, Marwan A.¹ (AUTHOR) malrasheed1@ksu.edu.sa, Alamer, Khalid A.² (AUTHOR) kaalamer@iau.edu.sa, Albishi, Mashael¹ (AUTHOR) oalmohammed@ksu.edu.sa, Alsuhibani, Abdulrahman A.³ (AUTHOR) aa.alsuhibani@qu.edu.sa, Almohammed, Omar A.¹ (AUTHOR) aalwhaibi@ksu.edu.sa, Alwhaibi, Abdulrahman¹ (AUTHOR), Almajed, Abdullah N.⁴ (AUTHOR) abdullah.n.almajid@gmail.com, Guo, Jeff J.⁵ (AUTHOR) guoje@ucmail.uc.edu

Source: Pharmaceuticals (14248247). Jul2024, Vol. 17 Issue 7, p815. 18p.

Subject Terms: *MULTIPLE myeloma, *DARATUMUMAB, *DATABASES, *DEATH rate, *MEDICAL personnel

Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma.

Authors: Dima, Danai^1,2 (AUTHOR), Mansour, Razan^2,3 (AUTHOR), Davis, James A.^2,4 (AUTHOR), Minchak, Megan^2,5 (AUTHOR), Goel, Utkarsh¹ (AUTHOR), Atallah, Rawan^2,3 (AUTHOR), Logan, Emerson^2,6 (AUTHOR), Tabak, Carine^2,6 (AUTHOR), Rashid, Aliya^2,3 (AUTHOR), Ahmed, Nausheen^2,3 (AUTHOR), Abdallah, Al‐Ola^2,3 (AUTHOR), Hashmi, Hamza^2,4,7 (AUTHOR) hamzahashmi87@hotmail.com

Source: European Journal of Haematology. Jun2024, Vol. 112 Issue 6, p975-983. 9p.

Subject Terms: *MULTIPLE myeloma, *DARATUMUMAB, *DEXAMETHASONE, *SURVIVAL rate, *LENALIDOMIDE

Successful treatment of scleromyxedema with daratumumab, lenalidomide and dexamethasone in a patient with multiple myeloma.

Authors: Bettolini, Luca¹ (AUTHOR) lbettolini@gmail.com, Bighetti, Stefano¹ (AUTHOR), Maione, Vincenzo¹ (AUTHOR), Ghini, Iacopo² (AUTHOR), Segala, Diego² (AUTHOR), Calzavara‐Pinton, Piergiacomo¹ (AUTHOR)

Source: Australasian Journal of Dermatology. Jun2024, Vol. 65 Issue 4, pe104-e107. 4p.

Subject Terms: *DARATUMUMAB, *MULTIPLE myeloma, *LENALIDOMIDE, *TREATMENT effectiveness, *MONOCLONAL gammopathies, *IMMUNOGLOBULIN light chains

Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.

Authors: Díaz-Tejedor, Andrea^1,2 (AUTHOR) adiaz062@usal.es, Rodríguez-Ubreva, Javier³ (AUTHOR) jrodriguez@carrerasresearch.org, Ciudad, Laura³ (AUTHOR) lciudad@carrerasresearch.org, Lorenzo-Mohamed, Mauro^1,2 (AUTHOR) lorenzomohamed.mauro@usal.es, González-Rodríguez, Marta^1,2 (AUTHOR) marta.gonzalez04@usal.es, Castellanos, Bárbara^1,2 (AUTHOR) barbaracas@usal.es, Sotolongo-Ravelo, Janet^1,2 (AUTHOR) sotolongojanet@usal.es, San-Segundo, Laura^1,2 (AUTHOR) duckey@usal.es, Corchete, Luis A.^1,2,4 (AUTHOR) lcorchetesanchez@mgh.harvard.edu, González-Méndez, Lorena^1,2 (AUTHOR) lgonzalez@usal.es, Martín-Sánchez, Montserrat^1,2 (AUTHOR) monseratt@usal.es, Mateos, María-Victoria^1,2,4,5 (AUTHOR) mvmateos@usal.es, Ocio, Enrique M.⁶ (AUTHOR) ocioem@unican.es, Garayoa, Mercedes^1,2 (AUTHOR) mgarayoa@usal.es, Paíno, Teresa^1,2,4,7 (AUTHOR) tpaino@usal.es

Source: International Journal of Molecular Sciences. May2024, Vol. 25 Issue 9, p4718. 15p.

Subject Terms: *DARATUMUMAB, *MULTIPLE myeloma, *CD38 antigen, *LIGANDS (Chemistry), *HISTONE deacetylase inhibitors

Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison.

Authors: Weisel, Katja¹ (AUTHOR), Dimopoulos, Meletios A.² (AUTHOR), Beksac, Meral³ (AUTHOR), Leleu, Xavier⁴ (AUTHOR), Richter, Joshua⁵ (AUTHOR), Heeg, Bart⁶ (AUTHOR), Patel, Sachin⁷ (AUTHOR), Majer, Istvan⁸ (AUTHOR), McFadden, Ian⁹ (AUTHOR), Mikhael, Joseph¹⁰ (AUTHOR) jmikhael@myeloma.org

Source: Leukemia & Lymphoma. Apr2024, Vol. 65 Issue 4, p481-492. 12p.

Subject Terms: *DARATUMUMAB, *MULTIPLE myeloma, *DEXAMETHASONE, *PROGRESSION-free survival, *LENALIDOMIDE

Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC).

Authors: Levin, Daniel¹ (AUTHOR), Lewis, Ellen¹ (AUTHOR), McCulloch, Sylvia¹ (AUTHOR), Lee, Holly¹ (AUTHOR), Tay, Jason^1,2 (AUTHOR), Duggan, Peter^1,2 (AUTHOR), Neri, Paola^1,2 (AUTHOR), Bahlis, Nizar^1,2 (AUTHOR), Jimenez-Zepeda, Victor H.^1,2 (AUTHOR) Victor.Zepeda@albertahealthservices.ca

Source: Leukemia & Lymphoma. Mar2024, Vol. 65 Issue 3, p403-406. 4p.

Subject Terms: *CARDIAC amyloidosis, *DARATUMUMAB, *AMYLOIDOSIS, *IMMUNOGLOBULIN light chains, *CLINICAL trials

A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient.

Authors: Yiğit Kaya, Süreyya¹ (AUTHOR) sureyyayigitkaya@hotmail.com, Vatani, Mehrad² (AUTHOR) mehradvt@gmail.com, Akil, Rima² (AUTHOR) dr.rimaakil@gmail.com, Cakir, Tansel³ (AUTHOR) tcakir@medipol.edu.tr, Maral, Senem¹ (AUTHOR) senemmaral@gmail.com, Kaynar, Leylagül¹ (AUTHOR) drleylagul@gmail.com, Sevindik, Ömür Gökmen¹ (AUTHOR) omurgok17@hotmail.com

Source: Annals of Hematology. Jan2025, Vol. 104 Issue 1, p829-833. 5p.

Subject Terms: *DARATUMUMAB, *VENETOCLAX, *DEXAMETHASONE, *CANCER treatment, *LYMPHOBLASTIC leukemia, *COMBINATION drug therapy, *AZACITIDINE

Early dFLC response by C1D7 predicts complete hematologic response in systemic AL amyloidosis.

Authors: Liu, Yang¹ (AUTHOR), Bi, Jingyi¹ (AUTHOR), Dou, Xuelin¹ (AUTHOR), Peng, Nan¹ (AUTHOR), Wen, Lei¹ (AUTHOR), Zhao, Yanqiu² (AUTHOR), Huang, Xiaojun¹ (AUTHOR), Lu, Jin^1,3 (AUTHOR) lujin@pku.edu.cn

Source: Annals of Hematology. Jan2025, Vol. 104 Issue 1, p617-625. 9p.

Subject Terms: *AMYLOIDOSIS, *DARATUMUMAB, *BORTEZOMIB, *BLOOD diseases, *STATISTICAL models, *OVERALL survival

Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.

Authors: Fu, Weijun¹ (AUTHOR), Bang, Soo-Mee² (AUTHOR), Huang, Honghui³ (AUTHOR), Kim, Kihyun⁴ (AUTHOR), Li, Wei⁵ (AUTHOR), An, Gang⁶ (AUTHOR), Lee, Je-Jung⁷ (AUTHOR), Cai, Zhen⁸ (AUTHOR), Jin, Jie⁸ (AUTHOR), Wang, Yafei⁹ (AUTHOR), Chim, Chor Sang¹⁰ (AUTHOR), Carson, Robin¹¹ (AUTHOR), Liu, Rui¹² (AUTHOR), Zhao, Man¹³ (AUTHOR), Chen, Xi¹⁴ (AUTHOR), Cui, Canchan¹⁵ (AUTHOR), Hou, Jian³ (AUTHOR) houjian@medmail.com.cn, Wang, Jianxiang⁶ (AUTHOR) wangjx@ihcams.ac.cn

Source: Annals of Hematology. Jan2025, Vol. 104 Issue 1, p515-525. 11p.

Subject Terms: *DARATUMUMAB, *BORTEZOMIB, *PREDNISONE, *ASIANS, *MELPHALAN, *MULTIPLE myeloma, *CLINICAL trials

Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.

Authors: Eleutherakis Papaiakovou, Evangelos¹ (AUTHOR) mdeleutherakis@gmail.com, Terpos, Evangelos¹ (AUTHOR), Kanellias, Nikolaos¹ (AUTHOR), Migkou, Magdalini¹ (AUTHOR), Gavriatopoulou, Maria¹ (AUTHOR), Ntanasis-Stathopoulos, Ioannis¹ (AUTHOR), Fotiou, Despoina¹ (AUTHOR), Malandrakis, Panagiotis¹ (AUTHOR), Theodorakakou, Foteini¹ (AUTHOR), Spiliopoulou, Vasiliki (AUTHOR), Kostopoulos, Ioannis V.² (AUTHOR), Tsitsiloni, Ourania² (AUTHOR), Tsirigotis, Panagiotis³ (AUTHOR), Dimopoulos, Meletios-Athanasios¹ (AUTHOR), Kastritis, Efstathios¹ (AUTHOR)

Source: Leukemia & Lymphoma. Dec2023, Vol. 64 Issue 13, p2140-2147. 8p.

Subject Terms: *STEM cell transplantation, *DARATUMUMAB, *STEM cells, *MULTIPLE myeloma

Refractory cold agglutinin disease successfully treated with daratumumab. A case report and review of literature.

Authors: Mohamed, Abdelaziz¹ (AUTHOR) Amohamed118@hamad.qa, Alkhatib, Mohammed¹ (AUTHOR), Alshurafa, Awni² (AUTHOR), El Omri, Halima² (AUTHOR)

Source: Hematology. Dec2023, Vol. 28 Issue 1, p1-5. 5p.

Subject Terms: *DARATUMUMAB, *MEMBRANE proteins, *TREATMENT effectiveness, *PLASMA cells, *PAROXYSMAL hemoglobinuria

Real-world experience with isatuximab in the treatment of relapsed-refractory multiple myeloma: a case series from the Grand Duchy of Luxembourg.

Authors: De Wilde, Sigrid¹ (AUTHOR) dewilde.sigrid@chl.lu, Plawny, Laurent¹ (AUTHOR), Berchem, Guy¹ (AUTHOR)

Source: Hematology. Dec2023, Vol. 28 Issue 1, p1-6. 6p.

Subject Terms: *MULTIPLE myeloma, *DARATUMUMAB, *MONOCLONAL antibodies, *PATIENT experience, *PATIENTS' attitudes

Geographic Terms: LUXEMBOURG

Adjunctive daratumumab can induce rapid remission in acquired haemophilia A with poor prognostic markers.

Authors: Moonla, Chatphatai^1,2 (AUTHOR), Polprasert, Chantana^1,2 (AUTHOR), Krittikarux, San³ (AUTHOR), Cheerasiri, Nuanrat^1,2 (AUTHOR), Akkawat, Benjaporn^1,2 (AUTHOR), Rojnuckarin, Ponlapat^1,2 (AUTHOR) rojnuckarinp@gmail.com, Uaprasert, Noppacharn^1,2 (AUTHOR)

Source: Haemophilia. Nov2023, Vol. 29 Issue 6, p1649-1652. 4p.

Subject Terms: *DARATUMUMAB, *PROGNOSIS, *BLOOD coagulation factors, *BLOOD coagulation factor VIII, *HEMOPHILIA

Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".

Authors: Mele, Giuseppe¹ (AUTHOR), Di Renzo, Nicola² (AUTHOR), Cascavilla, Nicola³ (AUTHOR), Carella, Angelo Michele³ (AUTHOR), Guarini, Attilio⁴ (AUTHOR), Mazza, Patrizio⁵ (AUTHOR), Melillo, Lorella⁶ (AUTHOR), Pavone, Vincenzo⁷ (AUTHOR), Tarantini, Giuseppe⁸ (AUTHOR), Curci, Paola⁹ (AUTHOR), Falcone, Anna P.² (AUTHOR), Germano, Candida⁸ (AUTHOR), Mele, Anna⁷ (AUTHOR), Merchionne, Francesca¹ (AUTHOR), Palazzo, Giulia⁵ (AUTHOR), Palumbo, Gaetano⁶ (AUTHOR), Quinto, Angela Maria⁵ (AUTHOR), Reddiconto, Giovanni³ (AUTHOR), Rossini, Bernardo⁴ (AUTHOR), Spina, Alessandro¹ (AUTHOR)

Source: Leukemia & Lymphoma. Oct2023, Vol. 64 Issue 10, p1715-1718. 4p.

Subject Terms: *DARATUMUMAB, *MULTIPLE myeloma, *BORTEZOMIB, *SUBGROUP analysis (Experimental design)

Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure.

Authors: Zamanillo, Irene¹ (AUTHOR) zamanillo.irene@gmail.com, Medina de Alba, Lucia¹ (AUTHOR), Gil, Rodrigo¹ (AUTHOR), de la Puerta, Rosalia² (AUTHOR), Alonso, Rafael¹ (AUTHOR), Jimenez-Ubieto, Ana¹ (AUTHOR), Cedena, Maria Teresa¹ (AUTHOR), Calbacho, Maria¹ (AUTHOR), Ayala, Rosa¹ (AUTHOR), Martinez-Lopez, Joaquin¹ (AUTHOR)

Source: Life (2075-1729). Sep2023, Vol. 13 Issue 9, p1841. 9p.

Subject Terms: *MULTIPLE myeloma, *DARATUMUMAB, *STEM cell transplantation, *TREATMENT effectiveness, *MONOCLONAL antibodies

Successful global anti‐B‐cell strategy with daratumumab in a patient with post‐transplant nephrotic syndrome recurrence unresponsive to immunoadsorption and obinutuzumab.

Authors: Delbet, Jean‐Daniel^1,2 (AUTHOR) jeandaniel.delbet@aphp.fr, Hogan, Julien^3,4,5 (AUTHOR), Parmentier, Cyrielle^1,2 (AUTHOR), Ulinski, Tim^1,2,6 (AUTHOR), Dossier, Claire^3,4 (AUTHOR)

Source: Pediatric Transplantation. Aug2023, Vol. 27 Issue 5, p1-4. 4p.

Subject Terms: *NEPHROTIC syndrome, *DARATUMUMAB, *IMMUNOADSORPTION, *PNEUMOCYSTIS pneumonia, *IMMUNOSUPPRESSIVE agents, *PNEUMOCYSTIS jiroveci

Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.

Authors: Nakamura, Naokazu^1,2 (AUTHOR) n_nakamura@kuhp.kyoto-u.ac.jp, Arima, Nobuyoshi¹ (AUTHOR), Takakuwa, Teruhito³ (AUTHOR), Yoshioka, Satoshi⁴ (AUTHOR), Imada, Kazunori⁴ (AUTHOR), Fukushima, Kentaro⁵ (AUTHOR), Hotta, Masaaki⁶ (AUTHOR), Fuchida, Shin-ichi⁷ (AUTHOR), Kanda, Junya² (AUTHOR), Uoshima, Nobuhiko⁸ (AUTHOR), Shimura, Yuji⁹ (AUTHOR), Tanaka, Hirokazu¹⁰ (AUTHOR), Ohta, Kensuke¹¹ (AUTHOR), Kosugi, Satoru¹² (AUTHOR), Yagi, Hideo¹³ (AUTHOR), Yoshihara, Satoshi¹⁴ (AUTHOR), Yamamura, Ryosuke¹⁵ (AUTHOR), Adachi, Yoko¹⁶ (AUTHOR), Hanamoto, Hitoshi¹⁷ (AUTHOR), Shibayama, Hirohiko¹⁸ (AUTHOR)

Source: Annals of Hematology. Dec2024, Vol. 103 Issue 12, p5681-5690. 10p.

Subject Terms: *MULTIPLE myeloma, *DARATUMUMAB, *OVERALL survival, *MULTIVARIATE analysis, *SUBGROUP analysis (Experimental design)

Efficacy and safety of daratumumab in multiresistant immune‐mediated thrombotic thrombocytopenic purpura.

Authors: Weisinger, Julia¹ (AUTHOR), Bouzid, Raïda^1,2 (AUTHOR), Ranta, Dana³ (AUTHOR), Woaye‐Hune, Pascal⁴ (AUTHOR), Cohen‐Aubart, Fleur⁵ (AUTHOR), Gaible, Clotilde⁶ (AUTHOR), Marjanovic, Zora¹ (AUTHOR), Corre, Elise¹ (AUTHOR), Joly, Anne‐Christine⁷ (AUTHOR), Baylatry, Minh‐Tam⁷ (AUTHOR), Joly, Berangère S.^1,2,8 (AUTHOR), Veyradier, Agnès^1,2,8 (AUTHOR), Coppo, Paul^1,2 (AUTHOR) paul.coppo@aphp.fr

Source: British Journal of Haematology. Nov2024, Vol. 205 Issue 5, p1951-1958. 8p.

Subject Terms: *THROMBOTIC microangiopathies, *DARATUMUMAB, *MONOCLONAL antibodies, *ACUTE diseases, *CD38 antigen

Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma.

Authors: Lee, Hyun-Woo¹ (AUTHOR), Kim, Sang-Mi¹ (AUTHOR), Park, Hyung-Doo^1,2 (AUTHOR) nayahyung@gmail.com

Source: Clinical Chemistry & Laboratory Medicine. Oct2024, Vol. 62 Issue 11, p2223-2232. 10p.

Subject Terms: *DARATUMUMAB, *BLOOD proteins, *MULTIPLE myeloma, *COMPARATIVE studies, *STATISTICAL reliability

Clinical efficacy of retreatment of daratumumab‐based therapy (D2) in daratumumab‐refractory multiple myeloma.

Authors: Abdallah, Al‐Ola^1,2 (AUTHOR) aabdallah@kumc.edu, Mahmoudjafari, Zahra^2,3 (AUTHOR), Ahmed, Nausheen^1,2 (AUTHOR), Cui, Wei^2,3 (AUTHOR), Shune, Leyla^1,2 (AUTHOR), McGuirk, Joseph¹ (AUTHOR), Mohan, Meera^2,4 (AUTHOR), Mohyuddin, Ghulam Rehman⁵ (AUTHOR), Afrough, Aimaz^2,6 (AUTHOR), Alkharabsheh, Omar^2,7 (AUTHOR), Atrash, Shebli^2,8 (AUTHOR)

Source: European Journal of Haematology. Jun2023, Vol. 110 Issue 6, p626-632. 7p.

Subject Terms: *MULTIPLE myeloma, *DARATUMUMAB, *PROTEASOME inhibitors, *EXTRAMEDULLARY diseases, *DATABASES, *PLASMACYTOMA